Antenatal glucocorticoids alter premature newborn lamb neuroendocrine and endocrine responses to hypoxia

M. GORE ERVIN,1 JAMES F. PADBURY,2 DANIEL H. POLK,3 MACHIKO IKEGAMI,4 LYNNE M. BERRY,5 AND ALAN H. JOBE4

1Department of Biology, Middle Tennessee State University, Murfreesboro, Tennessee 37132; 2Department of Pediatrics, Women’s and Infants Hospital of Rhode Island, Brown University, Providence, Rhode Island 02905; 3Children’s Memorial Hospital, Northwestern University Medical School, Chicago, Illinois 60614; 4Children’s Hospital Medical Center, Division of Pulmonary Biology, Cincinnati, Ohio 45229; and 5Perinatal Research Laboratories, Department of Pediatrics, University of California, Los Angeles School of Medicine, Harbor-University of California Los Angeles Medical Center, Torrance, California 90502

Received 4 January 2000; accepted in final form 5 April 2000

Ervin, M. Gore, James F. Padbury, Daniel H. Polk, Machiko Ikegami, Lynne M. Berry, and Alan H. Jobe. Antenatal glucocorticoids alter premature newborn lamb neuroendocrine and endocrine responses to hypoxia. Am J Physiol Regulatory Integrative Comp Physiol 279: R830–R838, 2000.—Glucocorticoids are administered for preterm labor to improve postnatal adaptation. We assessed the effect of antenatal betamethasone (Beta) treatment on preterm newborn lamb neuroendocrine [catecholamine, arginine vasopressin (AVP)] and endocrine [triiodothyronine (T3), ANG II, and atrial natriuretic factor (ANF)] adaptive responses following delivery and a hypoxic challenge. Beta treatment included direct fetal injection at 0.2 (F0.2; n = 8) or 0.5 (F0.5; n = 7) mg/kg estimated fetal body weight or maternal injection with 0.2 (n = 8) or 0.5 mg/kg (M0.5; n = 8). Control animals received fetal and maternal intramuscular injections of saline (n = 8). After 24 h, lambs were delivered by cesarean section, surfactant treated, and ventilated for 4 h. Relative to the control lambs, 3 h after delivery, there was a marked suppression of plasma cortisol, epinephrine, norepinephrine, and ANG II levels and elevated plasma T3 and ANF levels, systolic blood pressure, and left ventricular contractility (dP/dt; F0.5 and M0.5) values in F0.5 and both maternal Beta-treated groups. However, Beta treatment augmented the cardiac output, cortisol, norepinephrine, AVP, and ANF responses to 20 min of hypoxia (Po2 = 25–30 mmHg). We concluded that short-term (24 h) antenatal glucocorticoid exposure 1) alters preterm newborn postnatal blood pressure regulation in the face of marked depression of plasma cortisol, catecholamine, and ANG II levels and 2) augments the postnatal neuroendocrine and endocrine responses to a hypoxic challenge.

MULTIPLE NEUROENDOCRINE [catecholamine, arginine vasopressin (AVP)] and endocrine factors [cortisol, ANG II, atrial natriuretic factor (ANF)] are important modulators of neonatal adaptation and regulation of mechanisms important to postnatal vascular tone, blood volume, and blood pressure. Antenatal glucocorticoid administration is now widely used to improve lung function in human premature newborns. However, studies in premature newborn lambs (9, 29, 31, 37, 38) and emerging human data (22, 28) indicate antenatal glucocorticoid administration can significantly augment the cardiovascular, renal, and metabolic changes essential to postnatal adaptation at birth. In addition, a variety of fetal glucocorticoid treatment paradigms have demonstrated glucocorticoid-induced attenuation of postnatal changes in circulating levels of a variety of vasoactive factors (epinephrine, norepinephrine, AVP, and ANG II). Neuroendocrine and endocrine factors are thought to be important modulators of newborn blood pressure adaptation at birth (29, 37, 38). However, glucocorticoid effects have been suggested to limit postnatal cardiovascular adaptive responses (16). Thus questions regarding glucocorticoid effects on overall postnatal adaptive potential deserve further study. This series of experiments assessed the impact of short-term (24 h) antenatal glucocorticoid exposure on preterm newborn cardiovascular and neuroendocrine adaptations at birth. In addition, preterm newborn lambs were challenged with a brief period of hypoxia to assess the impact of antenatal glucocorticoid exposure on postnatal cardiovascular, neuroendocrine, and endocrine system responsiveness.

METHODS

Animal protocols were reviewed and approved by the Harbor-UCLA Animal Care and Use Review Committee. Pregnant ewes with singleton fetuses (n = 39) at 126 or 127 days gestational age were randomized into one of four betamethasone treatment groups or a saline-treated group (control). All ewes and fetuses received fetal and maternal injections with saline or betamethasone. Control animals received two (fetal...
and maternal) saline injections. On the basis of an estimated fetal weight of 2.5 kg, fetuses received ultrasound-guided intramuscular injections of saline or betamethasone (Celestone Soluspan®; Schering Pharmaceutical, Kenilworth, NJ) at 0.2 (F_0.2; n = 8) or 0.5 (F_0.5; n = 7) mg/kg as previously detailed (14). Maternal betamethasone treatments included 0.2 (M_0.2; n = 8) or 0.5 (M_0.5; n = 8) mg/kg. The 0.2 and 0.5 mg/kg fetal doses were selected based on our previous experience with fetal therapy (38). The M_0.2 dose was chosen to mimic the 12-mg total betamethasone dose used clinically and previously demonstrated to induce fetal lung maturation in sheep (23). The M_0.5 dose was selected to match the high-dose fetal treatment. The postnatal pulmonary and renal responses for some of these animals were reported elsewhere (2, 33). The focus of this report is the effect of antenatal glucocorticoid exposure on the preterm newborn postnatal neuroendocrine and endocrine system adaptations and the responses to the stress of hypoxia.

Ewes were sedated 24 h after treatments with 15–20 mg/kg im ketamine (Ketaject®; Phoenix Pharmaceutical, St. Joseph, MO) and given combined spinal-epidural anesthesia with 10 ml of 2% lidocaine/0.5% bupivacaine (1:1). The fetal head and neck were exposed through a small hysterotomy. The fetus was sedated with a ketamine (10 mg/kg im) and acepromazine (0.2 mg/kg im; PromAce®; Ayerst Laboratories, New York, NY) mixture administered on the basis of estimated fetal body weight. Although possible adverse effects of sedation cannot be excluded, this ketamine/acepromazine mixture has been used extensively without apparent detrimental effects on preterm newborn blood pressure, heart rate, and cardiac output (2, 9, 29, 33). The anterior neck was infiltrated with 2% lidocaine, an endotracheal tube was secured by tracheotomy, and lung liquid was aspirated. After delivery, lambs were towel dried, weighed, and treated with 100 mg/kg surfactant (Survanta®; Ross Laboratories; Columbus, OH) via direct intratracheal instillation. Lambs were mechanically ventilated with pressure-limited infant ventilators (Sechrist, Anaheim, CA) set to deliver 100% O_2. Initial ventilator settings were a positive end expiratory pressure of 3 cmH_2O, a rate of 40 breaths/min, and an inspiratory time of 0.7 s. Only peak inspiratory pressure (PIP) was adjusted to maintain PCO_2 values of 40–50 mmHg. PIP was limited to 35 cmH_2O to avoid pneumothorax. After delivery of the lamb, lambs were blotted to avoid hypothermia. Body temperature was monitored continuously via pressure transducers connected to a Beckman R-612 polygraph (Beckman Instruments; San Ramon, CA). Heart rate was computed from the arterial pulse. In addition to the continuous paper hardcopy, data were continuously streamed (20 Hz/channel) to an AT microcomputer by use of CODAS acquisition software (DATAQ Instruments; Akron, OH). Mean blood pressure and heart rate values were derived by post hoc analysis of the acquired data.

Cardiac output was assessed by injecting 5 ml of maternal blood containing known amounts of either ^57Co- or ^85Sr-labeled 15-μm microspheres into the left ventricle over 15 s. During the left ventricular injection, a reference sample was withdrawn (5 ml/min for 2 min) from the distal aorta with a Harvard pump (Harvard Apparatus, South Natick, MA) into a preweighed, heparinized syringe. The volume of blood withdrawn was determined gravimetrically, and microsphere content was assessed in an LKB Compugamma counter.

**Analytical techniques.** Blood pH, P_O2, and P_CO2 values were determined with a NOVA Stat Profile Plus 3 blood analyzer (NOVA Biomedical; Waltham, MA). Blood samples were divided immediately after withdrawal into chilled test tubes for determinations of catecholamines (4 mM EGTA and 3 mM reduced glutathione), cortisol, T_3, T_4, and AVP (lithium heparin; 40 μg/ml blood) and ANG II and ANF levels (aprotinin, 500 KIU/ml blood and K_2EDTA, 1 mM). Tubes were vortexed, centrifuged immediately at 4°C, and plasma aliquots frozen for extraction and/or analysis within 2–4 wk. Plasma catecholamine levels were determined by radioenzymatic assay sensitive to 1–2 pg/tube, with intra- and interassay coefficients of variation of <5% (38). Plasma cortisol, T_3, and T_4 levels were determined with chemiluminescence kits (Nichols Diagnostics; San Juan Capistrano, CA) standardized for ovine fetal plasma. Plasma AVP extraction and RIA were performed as previously described (10, 42); assay sensitivity is 0.8 pg AVP/tube, with intra- and interassay coefficients of variation of 6 and 9%, respectively. Plasma
ANF determinations were conducted by RIA, with an assay sensitivity of 2 pg/tube and intra- and interassay coefficients of variation of 11 and 13%, respectively (12). Plasma ANG II levels were determined from the ANF plasma extracts by use of RIA kits obtained from Peninsula Laboratories (Belmont, CA). Intra- and interassay coefficients of variation for the ANG II assay averaged 6 and 9%, respectively, with an overall assay sensitivity of 2 pg/tube.

Data analysis. All values are expressed as the mean ± SE. Differences over time and among saline- and betamethasone-treated groups were assessed by repeated-measures two-way analysis of variance with time as the within-subjects factor and treatment as the among-subjects factor. Multiple-comparison procedures included either the Student-Newman Keuls or Dunnett’s test, as appropriate. For endocrine values, the average of the 120- and 180-min values were used as the prehypoxia value, and the 190- and 200-min values represented the hypoxia values. Statistical significance for all analyses was accepted at \( P < 0.05 \).

RESULTS

Umbilical artery blood gas and pH values were in the normal range and were similar for all groups at delivery except for significantly higher arterial pH values in the F0.5, M0.2, and M0.5 groups relative to the control group. Arterial blood gas and pH values before (prehypoxia) and after the onset of hypoxia and 1 h after initiation of hypoxia (recovery) are summarized in Table 1. There were no changes in P\( \text{CO}_2 \) with time or among the groups at any time. Prehypoxia arterial P\( \text{O}_2 \) values were similar in the control and F0.2 groups. However, arterial P\( \text{O}_2 \) values were significantly higher in the other groups of animals treated with antenatal glucocorticoids regardless of route of administration or dose. Similar degrees of hypoxia were achieved in all groups treated with betamethasone relative to the control group and were significantly suppressed in the F0.5 and M0.2 groups relative to control lambs (Fig. 2). Plasma cortisol levels in control lambs significantly increased postnatally (prehypoxia) relative to the umbilical cord values. Although plasma cortisol levels increased postnatally in the F0.2 and M0.2 animals, the levels achieved were more than twofold below the control prehypoxia values. Plasma cortisol levels did not increase postnatally in the high-betamethasone dose (F0.5 or M0.5) groups, and the prehypoxia cortisol levels in the betamethasone-treated groups were significantly reduced relative to the control values. Hypoxia significantly increased plasma cortisol levels in both the M0.2 and M0.5 groups, whereas hypoxia had no effect on plasma cortisol levels in the control, F0.2, and F0.5 groups. Peak plasma cortisol levels during hypoxia were reduced in all betamethasone-treated groups relative to the control group (Fig. 2).

Table 1. Arterial blood gas and pH values in preterm newborn lambs

<table>
<thead>
<tr>
<th>Betamethasone, mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
</tr>
<tr>
<td>P( \text{CO}_2 ), mmHg</td>
</tr>
<tr>
<td>Cord</td>
</tr>
<tr>
<td>Prehypoxia</td>
</tr>
<tr>
<td>Hypoxia</td>
</tr>
<tr>
<td>Recovery</td>
</tr>
<tr>
<td>P( \text{O}_2 ), mmHg</td>
</tr>
<tr>
<td>Cord</td>
</tr>
<tr>
<td>Prehypoxia</td>
</tr>
<tr>
<td>Hypoxia</td>
</tr>
<tr>
<td>Recovery</td>
</tr>
<tr>
<td>pH</td>
</tr>
<tr>
<td>Cord</td>
</tr>
<tr>
<td>Prehypoxia</td>
</tr>
<tr>
<td>Hypoxia</td>
</tr>
<tr>
<td>Recovery</td>
</tr>
</tbody>
</table>

Values are means ± SE; \( n \), no. of animals. *Differs from control value; all hypoxia P\( \text{O}_2 \) values were significantly below the prehypoxia values.
Umbilical cord plasma $T_3$ levels were significantly elevated in all betamethasone-treated groups relative to the control group (Fig. 2). Mean plasma $T_3$ levels increased in all groups postnatally. Prehypoxia plasma $T_3$ levels in all betamethasone-treated groups were at least twofold above the control group values. However, plasma $T_3$ levels did not change in any group in response to hypoxia. Whereas the umbilical cord plasma $T_4$ levels tended to be lower in the maternal betamethasone-treated groups relative to the control value of 11.3 ± 0.5 ng/ml, there were no changes in plasma $T_4$ values in any group in response to hypoxia (data not shown).

The umbilical cord plasma epinephrine values tended to be lower in the lambs exposed to antenatal betamethasone. However, the level of suppression was statistically significant only in the M0.5 group. Control lamb plasma epinephrine levels significantly increased to ≈1,500 pg/ml postnatally (prehypoxia). In contrast, plasma epinephrine levels were suppressed in the F0.5 and both maternal betamethasone-treated groups before hypoxia (Fig. 3). Plasma epinephrine levels did not change in response to hypoxia, except in the M0.2 group.
group. Although mean plasma epinephrine levels achieved in response to hypoxia in the betamethasone-treated groups were, at most, only 40% (F0.5) of the control group hypoxia values, the degree of suppression was statistically significant only in the M0.5 group.

Umbilical cord plasma norepinephrine levels were not different among the groups (Fig. 3). Although mean plasma norepinephrine levels increased more than twofold postnatally in the control lambs, the change was not statistically significant. In contrast, postnatal plasma norepinephrine levels were significantly suppressed in the F0.5, M0.2, and M0.5 groups relative to the control values. Plasma norepinephrine levels did not change in response to hypoxia in the control group but significantly increased in all betamethasone-treated groups (Fig. 3). However, the peak hypoxia-induced plasma norepinephrine values achieved were not different between the control and betamethasone-treated groups.

The umbilical cord plasma AVP levels did not differ significantly among the groups, although plasma AVP levels were twofold lower in the F0.5 and both maternal betamethasone-treated groups. Plasma AVP levels increased postnatally in the M0.2 group but did not differ among the groups before initiation of hypoxia (Fig. 4). Whereas plasma AVP levels did not change in the control and F0.2 groups in response to hypoxia, plasma AVP levels increased three- to fivefold in the remaining betamethasone-treated groups. In contrast to the catecholamine and AVP responses, umbilical cord plasma ANF levels were significantly increased in the F0.5, M0.2, and M0.5 groups. Plasma ANF levels did not change in any group postnatally, although plasma ANF levels in the F0.2 and M0.5 groups were significantly elevated relative to the control group hypoxia values. Plasma ANF levels increased significantly in all groups in response to hypoxia. The change in plasma ANF levels in the betamethasone-treated groups was, on average, larger than in the control lambs, and the increase was significantly larger in the M0.2 and M0.5 groups.

Although there was a more than twofold suppression of umbilical cord plasma ANG II levels in all betamethasone-treated groups, the suppression was not statistically significant. (Fig. 4). However, hypoxia-induced plasma ANG II levels were significantly suppressed in the F0.5 and both maternal betamethasone-treated lambs relative to the control group. Plasma ANG II levels did not change in any group in response to hypoxia, and plasma ANG II levels in the F0.5 and M0.2 groups were significantly reduced relative to the control values during hypoxia.

DISCUSSION

The transition from fetal to newborn life is associated with marked changes in function of the major organ systems. Our prior studies examining the effects of antenatal glucocorticoid exposure on postnatal physiological adaptation in sheep have demonstrated improvements in pulmonary, cardiovascular, metabolic, and renal adaptation at birth (2, 9, 29, 31, 37, 38). However, we have also observed glucocorticoid-related reductions in the circulating levels of multiple neuroendocrine and endocrine systems thought to be critical to neonatal adaptation. Thus it was unclear whether these alterations in circulating hormone levels represented inhibition of secretion and/or an inability to respond to the physiological stress associated with prematurity.

In the present studies, we delivered control and betamethasone-treated preterm lambs, monitored their physiological adjustments over 3 h postnatally, and tested neuroendocrine and endocrine responsiveness to hypoxia. The studies included groups given glucocorticoids by direct fetal injection, a paradigm we have extensively investigated (2, 9, 14, 29, 31, 33). Other groups received a maternal betamethasone dose equivalent to the dose used clinically (M0.2) and a higher maternal dose chosen to achieve fetal plasma betamethasone levels similar to the lower direct fetal dose (2). Our results demonstrate that, in general, single antenatal glucocorticoid treatment within 24 h of preterm delivery suppresses postnatal circulating cortisol, catecholamine, AVP, and ANG II levels and increases circulating levels of T3 and ANF. Irrespective of these endocrine effects, betamethasone treatment
also resulted in postnatal increases in systolic blood pressure and left ventricular dP/dt. Moreover, antenatal glucocorticoid exposure attenuated the expected epinephrine response to hypoxia while augmenting the norepinephrine, AVP, and ANF responses. Overall, responses to glucocorticoid exposure were independent of the route of administration (fetal vs. maternal), and the magnitude of the endocrine responses to fetal glucocorticoid treatment was clearly dose related.

Despite no differences in heart rate or cardiac output, the \( P_{O_2} \) and both maternal betamethasone-treatment groups had higher systolic blood pressures relative to the control lambs. Thus the higher systolic blood pressure primarily reflects an increase in systemic vascular resistance (7). Elevations in fetal plasma glucocorticoid levels via a number of differing treatment paradigms increase resting fetal and preterm newborn mean arterial blood pressures (29, 38, 39), and Derks et al. (7) reported an association between glucocorticoid-induced increases in fetal blood pressure and an increase in femoral vascular resistance. Sustained elevation (24 h or more) in newborn mean arterial blood pressures after glucocorticoid exposure have now been reported from premature newborn sheep (29), baboons (11), and humans (15).

The available data indicate that glucocorticoid-induced increases in blood pressure are solely attributable to glucocorticoid receptors and not mineralocorticoid receptors (7). Because this phenomenon is gestation dependent in sheep, i.e., blood pressure effects are absent after 130 days gestation (39), augmented autonomic nervous system maturation may be a critical component in the overall cardiovascular response to antenatal glucocorticoid administration. Although the dP/dt measurements provide only a crude index of cardiac function, the parallels between systolic blood pressure and peak left ventricular pressure and the increases in left ventricular dP/dt are consistent with glucocorticoid-related increases in overall cardiac contractility (29). This latter effect appears to be related to augmented adrenergic receptor-dependent myocardial cyclic AMP production (38) and not increased receptor density in the heart. In addition, the elevated plasma \( T_3 \) levels observed in the betamethasone-treated lambs may have contributed to the overall improved myocardial function in these animals.

Despite the increase in resting blood pressure and a pattern of overall advanced maturation, the cardiovascular responses to hypoxia were inconsistent and limited to a small increase in blood pressure in the \( F_{O_2.5} \) group and increases in cardiac output in both fetal treatment groups. These minimal responses are in marked contrast to the pronounced responses of the chronically catheterized fetal lamb to periods of hypoxia (13). One explanation is the absence of changes in arterial blood \( P_{CO_2} \) and/or \( pH \) may have limited the cardiovascular responses (32). Alternatively, the degree of hypoxia achieved may not have been sufficient to elicit some of the cardiovascular responses. Although an arterial \( P_{O_2} \) value of 25 mmHg is clearly in the hypoxic range for a lamb or adult ewe, this \( P_{O_2} \) level is at the upper range of normal fetal arterial \( P_{O_2} \) values. This suggests that resetting of the chemoreceptor threshold from a fetal level to a higher adult level had not occurred by 3 h postnatally. Whether this resetting is related to peripheral chemoreceptor function cannot be assessed from the present experiments. However, robust hypoxia-induced AVP and ANF responses in the absence of cardiovascular effects is a response pattern consistent with the view that central oxygen-sensitive site(s) may develop before peripheral chemoreceptor activation in the fetus (17).

Our laboratory and others have reported exponential increases in the plasma levels of a number of vasoactive mediators at birth (24, 30), including increases in circulating epinephrine, norepinephrine, and AVP. The increase in circulating levels of both epinephrine and norepinephrine are significantly greater in preterm than in full-term animals (30). Because fetal chemical sympathectomy significantly obtunds postnatal increases in circulating norepinephrine (1) and fetal adrenalectomy completely abolishes the postnatal increase in circulating epinephrine, circulating norepinephrine responses reflect neuronal spillover, whereas epinephrine release represents adrenal medullary function. Although norepinephrine depletion from the fetal circulation is without effect on overall physiological adaptive potential (1), adrenalectomy markedly impairs cardiovascular, pulmonary, and metabolic adaptation in the immediate postnatal period (27). Thus even though an increase in circulating epinephrine at birth is thought to be important to many of the major physiological adaptations (27, 30), antenatal betamethasone treatment was associated with overall improvements in cardiovascular and pulmonary function (33) in the face of a marked suppression of circulating catecholamine levels. A similar attenuation of circulating catecholamine levels concomitant with increased blood pressure has been reported in fetal sheep during infusion of cortisol (43) and betamethasone/dexamethasone (7).

Glucocorticoid administration increases fetal arterial blood pressure (7), decreases fetal and newborn plasma catecholamine and ACTH stress responses (18, 26, 34), and decreases central sympathoadrenal activity in adult rats (19, 41). This latter effect has been documented by both microdialysis studies (41) and by examination of changes in regional neurotransmitter content as an index of nervous system activity (19). Because the betamethasone-treated animals had attenuated postnatal catecholamine responses, antenatal glucocorticoids may act by inhibiting or attenuating baroreceptor- and/or vestibular-mediated central sympathetic outflow. Whether this effect is related to an apparent resetting of baroreflex-mediated blood pressure regulation in the betamethasone-treated lambs is not clear. Other investigators have proposed that regulation of sympathoadrenal and hypothalamo-pituitary-adrenal system activity is colocalized and coregulated coordinately via central mechanisms (18, 26). Plasma catecholamine, ACTH, and cortisol levels increase after adrenalectomy, and the response of each of
these systems to an immobilization stress is augmented (26).

The betamethasone-induced suppression of plasma cortisol and ANG II levels and the more than 50% reduction in plasma AVP levels in the F₀.₅ and both maternal betamethasone-treated groups are consistent with the acute effects of cortisol infusion on these systems. Although plasma ACTH levels were not assessed in the current studies, it appears likely the betamethasone-induced suppression of preterm newborn plasma cortisol levels reflects feedback inhibition to suppress ACTH release. Whereas the exact mechanism for betamethasone-related reductions in plasma AVP levels is not known, baroreflex-related attenuation of AVP release due to the higher fetal blood pressures and the dense accumulation of glucocorticoid receptors in the anterior hypothalamus adjacent to AVP regulatory neurons may be important contributing factors (21).

Glucocorticoid administration also was associated with marked attenuation of the renin-angiotensin system (Fig. 4). The suppression of circulating ANG II levels can be explained by glucocorticoid-induced suppression of both renal renin gene expression (36) and plasma renin activity (44) and hepatic angiotensinogen gene expression (3, 25). A betamethasone-mediated suppression of the renin-angiotensin system is surprising from the perspective that, due to nervous system immaturity, circulating ANG II is a critical determinant of preterm fetal peripheral vasoconstriction and blood pressure and overall blood pressure regulation. For example, administration of the ANG II antagonist saralasin or the angiotensin-converting enzyme inhibitor captopril decreases resting blood pressure to a much greater extent in preterm than in near-term fetal lambs (20). This apparent discrepancy may be partially explained by glucocorticoid-induced increases in vascular ANG II AT₁-receptor expression and increased vascular responsiveness to ANG II (35, 39). These effects, in combination with glucocorticoid-induced autonomic nervous system maturation, discussed above, may be important aspects of the overall glucocorticoid-induced effect to increase fetal blood pressure.

The augmented ANF response to hypoxia in the present study was unexpected. Whereas hypoxia has been shown to be a potent stimulus for ovine fetal ANF secretion (13), ANF responsiveness is typically thought to be inversely related to advancing gestational age (5). Basal fetal plasma ANF levels are typically high and decrease with advancing gestation. If glucocorticoids induce fetal maturation, we would have expected umbilical cord ANF levels to be suppressed in the betamethasone-treated animals, which was not the case (Fig. 4). Alternatively, the glucocorticoid-induced increase in blood pressure and vascular resistance may have increased venous return and/or right atrial pressure sufficiently to increase plasma ANF levels (5). Because cardiac cell ANF release is at least partially dependent on both α- and β-adrenergic receptor mechanisms, a glucocorticoid-induced increase in β-adrenergic receptor effector system coupling (38, 40) may have contributed to the augmented ANF response observed in the betamethasone-treated lambs.

There are several potentially important clinical implications of these studies. Clinical epidemiologic and demographic studies have consistently demonstrated that antenatal glucocorticoid exposure of the human fetus significantly reduces mortality in the premature newborn (6). We and others have suggested this effect is due not only to accelerated pulmonary maturation, but improvement in physiological, cardiovascular, metabolic, and endocrine changes at birth (28). The present studies confirm and extend these observations by providing direct evidence that antenatal glucocorticoids do not impair the physiological responses to postnatal stressful events such as hypoxia. Thus glucocorticoids attenuated the circulating levels of a variety of vasoactive agents (catecholamines, AVP, and ANG II), whereas pulmonary function, blood pressure, cardiac output, and metabolic activity were all maintained, and the critical physiological responses to a stressful postnatal event (hypoxia) were not impaired.

**Perspectives**

Antenatal glucocorticoid administration has gained wide acceptance as an effective therapeutic approach to reducing postnatal morbidity and mortality due to lung immaturity in premature human infants. However, as clearly demonstrated by the present and previous studies, glucocorticoid-related effects on the preterm newborn are not limited to the lungs. In fact, glucocorticoid-induced cardiovascular effects appear to contribute to improved perinatal blood pressure regulation in the premature human newborn (22). Whereas these collective beneficial effects have important clinical applications, concerns also have been raised. For example, emerging data from a variety of sources suggest that antenatal glucocorticoid administration may predispose the individual to vascular hypertension later in life (8). It is therefore essential that future research focus on distinguishing the basic mechanisms for glucocorticoid-induced pulmonary versus cardiovascular effects so that more specific therapeutic agents might be developed or identified.

The authors gratefully acknowledge the contributions of Glenda Calvario, James Humme, Leslie Blount, James Surdilla, and Kent Kashiwai to the completion of these studies.

This work was supported in part by Grant HD-29713 from the National Institute of Child Health and Human Development, by the National Institutes of Health, and an Established Investigatorship Award to M. G. Ervin from American Heart Association.

**REFERENCES**


3. Carbone GMR, Sheikh AU, Zehnder T, and Rose JC. Effect of chronic infusion of cortisol on renin gene expression and renin

